Annual Luau and Legends of Surfing Invitational to make virtual waves – For the first time ever surfers scientists physicians and survivors will come…

On. Aug. 19, Dane Perlee rides a wave during the Luau & Legends of Surfing Invitational. PHOTOSBYJOHNCOCOZZA

For the first time ever, surfers, scientists, physicians and survivors will come together virtually to support the fight against cancer at the annualLuau and Legends of Surfing Invitationalon Aug. 9.

As UC San Diego events are being canceled or postponed because of the coronavirus pandemic, the annual fundraiser has transitioned to a virtual format to allow participants to support the fight against cancer from home.

Instead of surfing the ocean, participants are invited to surf the wave of cancer research as theyCrowdsurf for a Cure, helping raise money for research, education and clinical care. All proceeds from the 27th annual Luau and Legends of Surfing Invitational will benefit Moores Cancer Center at UC San Diego Health and contribute to the Campaign for UC San Diego.

As we celebrate the 27th Luau and Legends of Surfing Invitational, it is inspiring to see the local community continue to support the breakthrough discoveries and life-saving treatment developed by Moores Cancer Center, said Dr. Scott M. Lippman, director of Moores Cancer Center at UC San Diego Health. While we cannot join together in person for this years event, cancer does not stop during the COVID-19 pandemic and neither does our commitment to finding new cures and treatments for this life-threatening disease. Thanks to the generous donations raised through the Luau, we can continue to provide our patients with the latest individualized treatment and excellence in patient care that is only available at an academic medical center like ours.

The beloved fundraiserwhich has traded tuxedos for wet suits and ballrooms for beach views since its founding in 1993has brought in nearly $10 million for research and helped thousands of cancer patients through clinical trials, new treatments and delivering discoveries. Now, amid nationwide pandemic-related disruptions to the health sector, support towards ending this devastating disease continues to be critical.

For myelofibrosis patient and advocate Sandra Dillon, this support made all the difference in her journey with cancer. When doctors discovered a small lump behind Dillons ribcage in 2004which turned out to be an enlarged spleen, a symptom of myelofibrosisit came completely out of the blue. As a healthy 28-year-old, the last thing she expected was to be diagnosed with an extremely rare cancer with no real treatment options and a median survival rate of five to seven years.

What I thought was my whole life ahead of me was now just a few years, said Dillon, whose doctors tried to manage her symptoms as she slowly got sicker from the disease. I had such a hard time with my diagnosis and my experience. Knowing that there was no treatment that could stop myelofibrosis, I just didn't want to see doctors, be in a hospital or take any more tests. I kind of gave up on medicine in general and figured, Well, Ill just take the time that I've got left and that's all I've got.

Several years later, the trajectory of Dillons life changed completely when she moved to San Diego and was introduced to the team at Moores Cancer Center. Ridden with fear and hesitancy, she made the courageous decision to continue to fight for her life with support from her friends and husband, Casey Turk.

What I found at Moores Cancer Center was the exact opposite of what I was expecting. I was greeted with so much compassion and care at every level, said Dillon, who came to the center in 2011. Initially, I was afraid of being a pin cushion and just a number passing through a system. Instead, I found a home. Moores Cancer Center is a shining light of what treatment and health care can, and should, look like.

At Moores Cancer Center, Dillon met physician-scientistDr. Catriona Jamieson, Deputy Director of Moores, who enrolled her in a clinical trial for a new drug called fedratinib designed to block cancer cell proliferation. The results were amazingin a few months, Dillon was revitalized with newfound energy, less pain and a whole new life.

However, when the promising cancer drug was discarded for safety concerns and its trial pulled, Jamieson and her team were forced to turn to alternate trials and treatments to halt Dillons disease. With the health of multiple patients depleting in the absence of fedratinib, Jamieson worked tirelessly alongside scientist, biotech executive and Moores Cancer Center Board Vice Chair John Hood, who has a doctorate in medical physiology and led early research on the drug, to fight to bring it back. When fedratinib was finally approved by the FDA in 2019, it was the first new therapy approved for myelofibrosis in nearly a decade. It is now available under the brand name Inrebic.

Now that I am on the drug, I havent had to have a blood transfusion in over a year. I feel incredible again, said Dillon. What Dr. Jamieson and Hood have accomplished is incredibleits a blessing for me and an amazing testament to what is possible.

During the online fundraiser on Aug. 9, Jamieson and Hood will both be recognized with the Rell Sunn Award, which honors the memory of Rell Kapoliokaehukai Sunn, known as the First Lady of Surfing. Sunn was diagnosed with breast cancer at the age of 32, but rather than submitting to the disease, she lived life to the fullest until passing 15 years later in 1998. The Rell Sunn Award recognizes individuals who have made a difference in the battle against cancer and who embody the Aloha spirit.

This event has had a sustainably positive impact on our relentless drive to deliver new discoveries to the clinic with alacrity, and our unique capacity at Moores Cancer Center to develop personalized cancer stem cell, immunotherapy, and precision-medicine-guided targeted therapies for hopeful patients across economic strata, said Jamieson. To receive this award is such an extraordinary privilege considering that it honors Rell Sunn, a champion Hawaiian surfer who battled breast cancer and was the personification of hope, joy and the spirit of ganbatte, which is the Japanese word for never, ever, ever, give up.

Being honored based on a person like Sunn, by your peers and neighbors, is incredible. I feel very grateful for it, said Hood. I hope what we didfacing down the FDA with a small group in the company and doing everything we can to get it to the patientswould make her proud.

The virtual luau festivities kick off online on Aug. 9 at 5 p.m. Guests can expect to enjoy a program featuring: an address from Chancellor Pradeep K. Khosla, Vice Chancellor for Health Sciences Dr. David Brenner and CEO of UC San Diego Health Patty Maysent, messages from surf legends, Moores Cancer Center leaders, Polynesian dancers, live music and more. Attendees in the local region can also join in by pre-ordering aDinner and Drinks packagea catered meal and cocktails with options to be picked up or delivered to their home to enjoy during the event. Featured artwork will be presented by Southern California surfer Andy Davis.

The Luau and Legends of Surfing Invitationals Crowdsurf for a Cure is free to register and to attend. Event sponsors include: Cooley LLP; Lina and Christian Waage; Lisa and Mike Rhodes; Valerie Ewell Armstrong and Sam Armstrong; BioMed Realty; ASML; Arey Jones; The Allergan Foundation; and Pfizer. For more information about sponsorship opportunities and event activities,visit the Luau and Legends of Surfing Invitational website. You can also get read more about theMoores Cancer Center at UC San Diego Health.

Gifts made through the 27th annual Luau and Legends of Surfing Invitationals Crowdsurf for a Cure also contribute to the Campaign for UC San Diegoa university-wide comprehensive fundraising effort concluding in 2022. Alongside UC San Diegos philanthropic partners, the university is continuing its nontraditional path toward revolutionary ideas, unexpected answers, lifesaving discoveries and planet-changing impact. For more information,visit campaign.ucsd.edu.

More here:
Annual Luau and Legends of Surfing Invitational to make virtual waves - For the first time ever surfers scientists physicians and survivors will come...

Ozzy Osbourne: I was convinced I was dying during nightmare health year – Dothan Eagle

Ozzy Osbourne was "convinced" he was dying amid his year plagued with health setbacks.

The 'Crazy Train' hitmaker suffered a nightmare year in 2019 which saw him endure several medical issues including a fall, neck surgery, an infection in his hand, and hospitalization for the flu.

And at the start of 2020, he revealed he had been diagnosed with Parkinson's - which is a brain disorder that leads to shaking, stiffness, and difficulty with walking, balance, and coordination - for which he later had stem cell treatment to try and ease the symptoms.

Discussing his year of ill health, Ozzy said: "I'm not back to 100 percent. I'm about 75 percent there, but it's such a slow recovery. Spine surgery is bad news, man. I've been in such a bad state with pain; I'm still having a lot of pain.

"There was a point I was convinced that I was dying. I was in that much discomfort and pain and misery. I thought they were all hiding it from me. I remember saying to Sharon, 'You've gotta level with me. Is it worse than you're making it out [to be]?' She says, 'No.' ... I've dropped all the medication for pain now."

And despite his health woes, the 71-year-old rocker is itching to get back on stage as soon as the coronavirus pandemic - which has forced all concerts to be cancelled - has passed.

He added in an interview for SiriusXM: "I cannot wait [to get on stage], but I was talking to Tony Iommi the other day, and he was saying with the way it's going with this coronavirus, indoor shows will be a thing of the past."

Follow this link:
Ozzy Osbourne: I was convinced I was dying during nightmare health year - Dothan Eagle

Stem Cell Therapy Market Is Forecasted To Register A CAGR Growth Of XX% Between And2020 – Bulletin Line

With having published myriads of reports, PMR imparts its stalwartness to clients existing all over the globe. Our dedicated team of experts deliver reports with accurate data extracted from trusted sources. We ride the wave of digitalization facilitate clients with the changing trends in various industries, regions and consumers. As customer satisfaction is our top priority, our analysts are available 24/7 to provide tailored business solutions to the clients.

In this new business intelligence report, PMR serves a platter of market forecast, structure, potential, and socioeconomic impacts associated with the global Stem Cell Therapy market. With Porters Five Forces and DROT analyses, the research study incorporates a comprehensive evaluation of the positive and negative factors, as well as the opportunities regarding the Stem Cell Therapy market.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/3253

The Stem Cell Therapy market report has been fragmented into important regions that showcase worthwhile growth to the vendors Region 1 (Country 1, Country 2), region 2 (Country 1, Country 2) and region 3 (Country 1, Country 2). Each geographic segment has been assessed based on supply-demand status, distribution, and pricing. Further, the study provides information about the local distributors with which the market players could create collaborations in a bid to sustain production footprint.

Prominent players operating in the Stem Cell Therapy market players consist of the following:

Some of the major companies operating in the global stem cell therapy market are Mesoblast Ltd., Celgene Corporation, Aastrom Biosciences, Inc. and StemCells, Inc.

Key points covered in the report

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/3253

What does the Stem Cell Therapy market report contain?

Readers can get the answers of the following questions while going through the Stem Cell Therapy market report:

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/3253

Go here to read the rest:
Stem Cell Therapy Market Is Forecasted To Register A CAGR Growth Of XX% Between And2020 - Bulletin Line

MediVet Biologics Rebrands as Ardent Animal Health – Benzinga

LEXINGTON, Ky., Aug. 3, 2020 /PRNewswire-PRWeb/ -- Introducing Ardent Animal Health MediVet Biologics rebrands company and positions its platform of innovative products for transformative growth

MediVet Biologics is announcing a new name and a new look for its corporate brand as it relaunches itself as Ardent Animal Health.

In the years since its inception in 2016, the new Ardent Animal Health has developed into a global leader in the areas of veterinary regenerative medicine and oncology solutions for animals. The company's core mission is to develop affordable, innovative treatments for animal cancer and disease while supporting its veterinary partners in their efforts to make a positive impact on pet health.

"The name 'Ardent' captures the spirit of our organization as a company with fiery passion for innovation guided by compassion for the well-being of animals. The new brand translates the enormous and unique impact our veterinarian customers make each day in the lives of their patients. Our aim is to leverage our brand to accelerate connecting pet owners seeking advanced care to our expanding network of progressive veterinarian partners around the world," says Thomas Masterson, President of Ardent Animal Health.

Under its former brand of MediVet Biologics, Ardent Animal Health developed the first in-clinic adipose regenerative stem cell therapy kit, ActiStem Therapy. A major scientific advancement in animal regenerative medicine, the product offers an economic solution for owners of pets suffering from osteoarthritis, hip dysplasia, and ligament and cartilage injuries, as well as numerous mobility ailments. In addition to regenerative cells from fat, Ardent-certified hospitals offer other biologic treatments such as Platelet Rich Plasma, or PRP, a blood-derived treatment gaining popularity in human sports medicine.

Ardent Animal Health is unique for a company of its size, as it has surrounded its current and pipeline products with strong intellectual property and multiple collaborative university studies. This has allowed the company to grow, cementing its current technology, and look toward the future for its stem cell-based product pipeline candidates. Ardent Animal Health will launch with an extensive following of pet owners and veterinarians positively impacted by its products and services. The studies, passionate customers, and patient outcomes continue to provide momentum for the company's technology and products. Over 20,000 veterinary patients have received treatment of an Ardent Animal Health regenerative product or service.

Ardent Animal Health has also introduced cutting edge science to fight against canine cancer with its cancer vaccine service, K9- ACV, an immunotherapy vaccine generated from a canine patient's own cancerous tumor. K9-ACV is designed to stimulate the canine patient's immune response to attack the cancer. "We are looking to meet an unmet need in pet cancer, at the family veterinarian office when needed. 50% of dogs over the age of ten will develop some type of cancer, so there is a need for a broadly applicable approach that can improve lifespan at a reasonable cost. Our preliminary studies and extensive market research indicate this approach will provide access to pets that need it," Masterson said.

According to Mr. Masterson, the company's strength in these core innovative therapeutic areas will allow the organization to accelerate growth following its recent transition in both leadership and ownership. As a portfolio company of STUCK Fund 1, based in Milwaukee, WI, Ardent Animal Health will continue to develop novel approaches for early disease detection and treatments, with a focus on precision medicine for pets in need.

"We will continue to focus much of our strategy in creating novel products and services utilized in veterinary hospitals. We believe that this approach is key to the future of animal health. It is important not only for value creation but to ensure veterinarians have the ability to diagnose and treat their patients with the same leading-edge strategies underway in human health. Our animal family members deserve it."

Disclaimer Experimental Cancer Vaccines created by Ardent Animal Health are provided under 9 CFR 103.3 via USDA Center for Veterinary Biologics oversight for use under supervision/prescription of a licensed veterinarian. Safety & efficacy have not been yet established.

About Ardent Animal Health

Since 2016 Ardent Animal Health based near Lexington, KY, has provided advanced medical strategies to veterinary hospitals around the world. Ardent provides regenerative medicine treatments such as ActiStem Therapy and PureVet PRP to veterinarians for pain and disease in companion and equine patients. Additionally, Ardent Animal Health is pursuing advanced strategies for detection and treatment of canine cancer. Through creation of its own intellectual property and strategic licensing partners, the company's portfolio includes current and future offerings aimed to raise the standard for animal healthcare.

Home

About STUCK Fund 1

Ardent Animal Health represents an innovation-focused element of the STUCK Fund 1 portfolio, as Ardent competes in the fast-growing and recession-resistant pet health sector. STUCK Fund 1, based in Milwaukee, WI, was founded in 2014 to live out the lessons the investment firm's founders learned from growing its business into an international, $100 million organization. STUCK founders were honored with numerous accolades in their prior ventures, including the Muskego Manufacturing Business of the Year award and the Waukesha Business Alliance Manufacturing Business of the Year honor, among several others. Currently, the investment firm supports like-minded entrepreneurs to accelerate and sustain the growth of their businesses.

About

Media Contact: Matt Yeich (859)885-7111 matt@ardentanimalhealth.com

SOURCE Ardent Animal Health

See the original post:
MediVet Biologics Rebrands as Ardent Animal Health - Benzinga

Automated Cell Culture Systems Market to Record Strong Growth due to High Demand for Advanced Treatment of Chronic Conditions, Future Market Insights…

Dubai, U.A.E, Aug. 3, 2020 /PRNewswire/ -- According to Future Market Insights, the automated cell culture systems marketwill exhibit a strong CAGR of 8% from 2020-2030.

Escalating incidences of chronic ailments have spurred greater research in cytology and cell biology for developing advanced diagnosis and treatment. This is largely an end-product of boundaries in conventional pharmaceuticals. Furthermore, growing complexities of the nature of chronic diseases is prompting various technological advancements with regard to treatment, thereby bolstering the scope of automated cell culture systems.

Greater penetration of 3D-cell cultures have significantly boosted the adoption of automated culture systems, as is the need for faster testing of biological or biochemical activities. Furthermore, requirement of cell lines to devise vaccines for COVID-19 shall catapult the automated cell culture market in the upcoming forecast period.

"Key players are developing specific and specialty growth media with the aid of various technological advancements, which is expected to sustain market growth over the following decade," infers an FMI analyst.

Request a Sample Report with Table of Contents and Figures: https://www.futuremarketinsights.com/reports/sample/rep-gb-7860

Key Takeaways from FMI's Automated Cell Structure Systems Report

Automated Cell Culture Systems Market- Key Trends

Automated Cell Culture Systems Market- Region-wise Analysis

Our advisory services are aimed at helping you with specific, customized insights that are relevant to your specific challenges. Let us know about your challenges and our trusted advisors will connect with you: https://www.futuremarketinsights.com/askus/rep-gb-7860

Automated Cell Culture Systems Market- Competitive Landscape

Prominent players are concentrating on offering new products, innovations and collaborations with other companies to widen their outreach across major geographical areas.

For instance, in July 2020, Sphere Fluidics announced a partnership with the Heriot-Watt University in Edinburgh for developing next generation droplet generator instrumentation. This agreement is for expanding its advanced biologics discovery and therapeutic cell line development.

Also, in February 2020, Selexis announced the application of Bioprocessing 4.0 by incorporating automated systems such as the ambr and Beacon optofluidic platforms for enhanced cell line development.

Request special price for this Report to our Sales [emailprotected]https://www.futuremarketinsights.com/request-special-price/rep-gb-7860

Automated Cell Culture Systems Market Taxonomy

Product Type

Cell Culture Type

Application

End User

Region/Country

Request the Coronavirus Impact Analysis across Industries and [emailprotected]https://www.futuremarketinsights.com/covid19/rep-gb-7860

More Insights on the Automated Cell Culture Systems Market

The study provides compelling insights on automated cell culture systems market on basis of product type (automated cell culture storage equipment, automated cell culture vessels, bioreactors and consumables), cell culture type (finite cell line cultures, infinite cell line cultures), application (drug development, stem cell research, regenerative medicine and cancer research) and end user (biotech companies, research organizations, academic institutes), and across seven major regions.

Explore Extensive Insights on FMI's Healthcare, Pharmaceuticals and Medical Devices Landscape

Fertility and Pregnancy Rapid Test Kits Market: Investigate a detailed bird's-eye view of FMI's fertility and pregnancy rapid test kits market by perusing the report for the upcoming decade's forecast period, bringing to the fore valuable insights responsible for shaping the growth trajectory during the forecast.

Home Healthcare Market: A surging geriatric population pool is leading to an increase in the prevalence of chronic disorders, ultimately boosting the need for home healthcare products in recent years, concludes FMI on its report on the home healthcare market for the 2020-2030 assessment period.

Gene Synthesis Market: The gene synthesis market study published by FMI incorporates a global industry analysis from 2014-2018 and opportunity assessment from 2019-2029, delivering a comprehensive outlook on prominent growth dynamics.

About Future Market Insights (FMI)

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries.FMIisheadquartered in London, the global financial capital, and has delivery centers in the U.S. and India. FMI's latestmarket research reportsandindustry analysis help businesses navigate challenges and take critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously track emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

ContactMr. Abhishek Budholiya Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A, Jumeirah Lakes Towers, Dubai, United Arab Emirates MARKET ACCESS DMCC Initiative For Sales Enquiries: [emailprotected] For Media Enquiries: [emailprotected]Report: https://www.futuremarketinsights.com/reports/automated-cell-culture-systems-market Press Release Source:https://www.futuremarketinsights.com/press-release/automated-cell-culture-systems-market

SOURCE Future Market Insights

Follow this link:
Automated Cell Culture Systems Market to Record Strong Growth due to High Demand for Advanced Treatment of Chronic Conditions, Future Market Insights...

CarthroniX President/Chairman of the Board R. Rex Parris and Carrol Parris Donate $50,000 in Support of Life Extension Research – PRNewswire

LANCASTER, Calif., Aug. 3, 2020 /PRNewswire/ -- R. Rex Parris, President and Chairman of the Board of biotech company CarthroniX, announced a donation of $50,000 to Denis Evseenko, MD, Ph.D. of the Keck School of Medicine of USC to support continued research in the field longevity.

Dr. Evseenko was recently awarded a $1.69 million research project grant from the National Institutes of Health to address how to slow arthritis in aging joints. He has helped develop breakthroughs in molecular studies that identified and characterized the unique cell populations that form the superficial human joint cartilage zone.

Dr. Evseenko is one of the world's leading medical researchers of arthritis and how gene activity drives cartilage development. "The CDC reports that 23% of all adults, or 54 million people, have some form of arthritis and are limited in their activities due to severe joint pain," said Mr. Parris. "Dr. Evseenko's work will help tens of millions of people in this country and many more worldwide, living with arthritis's daily struggle. Now there is evidence that it will also extend the quality of life and longevity."

CarthroniX is comprised of scientists and surgeons with expertise in regenerative medicine and stem cell research. Their research is focused on creating novel small molecules to stimulate the regrowth of healthy cartilage. Dr. Evseenko's work fits seamlessly with CarthroniX's goals of extending the quality of life for millions of people. Osteoarthritis is one component of the aging process as cartilage degenerates over time, especially after injury and wear and tear.

Recently it was discovered that some of the small molecules studied to treat arthritis also reverse the aging of human cells in vitro. This gift will enable Dr. Evseenko's lab to advance to the next stage of research. The CX-1 small molecule will hopefully slow the aging of mice. If this is confirmed, CarthroniX will seek FDA approval of human trials to investigate CX-1's effect on human longevity and regeneration of vital organs. "This gift will help us explore some fundamental and transformative questions related to life span extension," said Dr. Evseenko.

CarthroniX novel technologies are proven to preserve, repair, and regenerate cartilage in joints and suppress inflammation in large animals. CarthroniX is developing two types of drugs: one that is both regenerative and anti-inflammatory, and a second that is solely anti-inflammatory.

ABOUT CarthroniX

CarthroniX is developing novel small molecules to stimulate the growth and regeneration of articular cartilage in joints. CarthroniX patented, first-in-class small molecule CX-1 activates an established regenerative pathway; they demonstrated this results in cartilage proliferation, cellular migration, and deposition of cartilaginous matrix.

Media Contact: Joe Marchelewski, [emailprotected]

SOURCE PARRIS Law Firm

Originally posted here:
CarthroniX President/Chairman of the Board R. Rex Parris and Carrol Parris Donate $50,000 in Support of Life Extension Research - PRNewswire

UPDATE – Cytovia Therapeutics Acquires Worldwide Rights to CytoImmune Therapeutics’ First-In-Class EGFR Dual-targeting CAR for NK Cell Treatment of…

August 03, 2020 15:36 ET | Source: Cytovia Therapeutics

NEW YORK and MONROVIA, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc (Cytovia), an emerging biopharmaceutical company developing natural killer (NK) immunotherapies for cancer, today announces that it has acquired worldwide rights from CytoImmune Therapeutics for its novel EGFR Dual-targeting CAR to be used for NK cell therapy. Cytovia will conduct and finance all future development and will apply the EGFR Dual-targeting CAR to its iPSC CAR NK technology. CytoImmune will receive an upfront equity grant in Cytovia, future development milestones, and royalties.

Dr. Daniel Teper, Chairman and CEO of Cytovia added: We are honored to collaborate with Dr. Caligiuri, a pioneer in translating biological research on NK cells into impactful therapeutics. He has published solid data with intracranial injection of EGFR CAR NK cells to support their clinical development in glioblastoma. Additionally, EGFR is a clinically validated target which will allow us to expand the use of NK cellular therapy in multiple solid tumors.

Pre-clinical proof of concept data with intracranial administration of the EGFR Dual-targeting CAR-NK cells for the treatment of glioblastoma has been published in Nature Scientific Reports. The EGFR Dual-targeting CAR targets glioblastoma cells expressing EGFR wild-type and/or the mutant EGFR vIII. A single intracranial injection of EGFR CAR NK cells reduced the growth of glioblastoma and showed a statistically significant improvement in survival in animal models. The intracranial injection of the EGFR CAR NK cells remained localized in the brain without entering the systemic circulation or infiltrating extracranial organs or tissues, thus limiting toxicity.

Michael A. Caligiuri, MD, the scientific founder of CytoImmune, has been invited and is planning to join the Cytovia Scientific Advisory Board. Dr Caligiuri is the Deana and Steve Campbell Physician in Chief Distinguished Chair and President of the City of Hope National Medical Center in Duarte, CA. Dr. Caligiuri is a world-renowned physician, scientist, builder, innovator, leader and visionary. He was elected a Member of the National Academy of Medicine for his work on NK cell biology and its clinical applications. He is a past President of the American Association for Cancer Research (AACR).

Dr Caligiuri commented: CAR NK cell therapy has the potential to transform cancer outcomes. We are excited to partner with Cytovia to rapidly bring EGFR Dual-targeting CAR NK cells, a next generation therapy, to patients with the ultimate goal of curing glioblastoma. Cytovias off-the-shelf iPSC CAR NK cell technology should increase the access to precision immunotherapy for many cancer patients.

ABOUT CAR NK CELL THERAPYChimeric Antigen Receptors (CAR) are fusion proteins that combine an extracellular antigen recognition domain with an intracellular co-stimulatory signaling domain. Natural Killer (NK) cells are modified genetically to allow insertion of a CAR. CAR NK cell therapy has demonstrated initial clinical relevance without the limitations of CAR-T, such as Cytokine Release Syndrome, neurotoxicity or Graft vs Host Disease (GVHD). Induced Pluripotent Stem Cells (iPSC) - derived CAR NKs are naturally allogeneic, available off-the-shelf and may be able to be administered on an outpatient basis. Recent developments with iPSC, an innovative technology, allow large quantities of homogeneous genetically modified CAR NK cells to be produced from a master cell bank, and thus hold promise to expand access of cell therapy for many patients.

ABOUT GLIOBLASTOMAGlioblastoma affects 290,000 new patients every year worldwide. Chemotherapy and radiotherapy lack specificity and provide limited efficacy along with high toxicity. The median overall survival from the time of diagnosis is only 14.6 months. Systemic and particularly intracranial or intratumoral immunotherapy, which can target localized and infiltrating cells, has shown initial promise in early clinical trials.

ABOUT CYTOVIA THERAPEUTICS, INC Cytovia Therapeutics Inc is an emerging biotechnology company that aims to accelerate patient access to transformational immunotherapies, addressing several of the most challenging unmet medical needs in cancer and severe acute infectious diseases. Cytovia focuses on Natural Killer (NK) cell biology and is leveraging multiple advanced patented technologies, including an induced pluripotent stem cell (iPSC) platform for CAR (Chimeric Antigen Receptors) NK cell therapy, next-generation precision gene-editing to enhance targeting of NK cells, and NK engager multi-functional antibodies. Our initial product portfolio focuses on both hematological malignancies such as multiple myeloma and solid tumors including hepatocellular carcinoma and glioblastoma. The company partners with the University of California San Francisco (UCSF), the New York Stem Cell Foundation (NYSCF) and the Hebrew University of Jerusalem. Learn more atwww.cytoviatx.com

ABOUT CYTOIMMUNE THERAPEUTICS CytoImmune Therapeutics (CytoImmune) is biotechnology company focused on the application of proprietary chimeric antigen receptors (CAR) for use in both off-the-shelf human natural killer (NK) cells and autologous cytotoxic effector T cells in the treatment of liquid and solid tumors. Our CoalesceNT platform harnesses the power of both a specific CAR and a different secretory bispecific antibody in a single construct to coordinate an immune response with CAR NK cells, cytolytic effector T cells, NK-T cells and g/d T cells. This combination of NK- and T-cell therapy expedites time-to-treatment and delivers a dynamic response that reflects both innate and adaptive immunity in an effort to reduce tumor evasion and the incidence of cancer recurrence.

Learn more at http://www.cytoimmune.com

Contact for media enquiries Sophie Badr Vice President, Corporate Affairs Sophie.badre@cytoviatx.com 1(929) 317 1565

Will Rossellini President will@cytoimmune.com 1(469) 222 2350

Read the rest here:
UPDATE - Cytovia Therapeutics Acquires Worldwide Rights to CytoImmune Therapeutics' First-In-Class EGFR Dual-targeting CAR for NK Cell Treatment of...

MediVet Biologics Rebrands as Ardent Animal Health – PR Web

Ardent Animal Health

LEXINGTON, Ky. (PRWEB) August 03, 2020

Introducing Ardent Animal Health MediVet Biologics rebrands company and positions its platform of innovative products for transformative growth

MediVet Biologics is announcing a new name and a new look for its corporate brand as it relaunches itself as Ardent Animal Health.

In the years since its inception in 2016, the new Ardent Animal Health has developed into a global leader in the areas of veterinary regenerative medicine and oncology solutions for animals. The companys core mission is to develop affordable, innovative treatments for animal cancer and disease while supporting its veterinary partners in their efforts to make a positive impact on pet health.

The name Ardent captures the spirit of our organization as a company with fiery passion for innovation guided by compassion for the well-being of animals. The new brand translates the enormous and unique impact our veterinarian customers make each day in the lives of their patients. Our aim is to leverage our brand to accelerate connecting pet owners seeking advanced care to our expanding network of progressive veterinarian partners around the world," says Thomas Masterson, President of Ardent Animal Health.

Under its former brand of MediVet Biologics, Ardent Animal Health developed the first in-clinic adipose regenerative stem cell therapy kit, ActiStem Therapy. A major scientific advancement in animal regenerative medicine, the product offers an economic solution for owners of pets suffering from osteoarthritis, hip dysplasia, and ligament and cartilage injuries, as well as numerous mobility ailments. In addition to regenerative cells from fat, Ardent-certified hospitals offer other biologic treatments such as Platelet Rich Plasma, or PRP, a blood-derived treatment gaining popularity in human sports medicine.

Ardent Animal Health is unique for a company of its size, as it has surrounded its current and pipeline products with strong intellectual property and multiple collaborative university studies. This has allowed the company to grow, cementing its current technology, and look toward the future for its stem cell-based product pipeline candidates. Ardent Animal Health will launch with an extensive following of pet owners and veterinarians positively impacted by its products and services. The studies, passionate customers, and patient outcomes continue to provide momentum for the companys technology and products. Over 20,000 veterinary patients have received treatment of an Ardent Animal Health regenerative product or service.

Ardent Animal Health has also introduced cutting edge science to fight against canine cancer with its cancer vaccine service, K9- ACV, an immunotherapy vaccine generated from a canine patients own cancerous tumor. K9-ACV is designed to stimulate the canine patient's immune response to attack the cancer. We are looking to meet an unmet need in pet cancer, at the family veterinarian office when needed. 50% of dogs over the age of ten will develop some type of cancer, so there is a need for a broadly applicable approach that can improve lifespan at a reasonable cost. Our preliminary studies and extensive market research indicate this approach will provide access to pets that need it, Masterson said.

According to Mr. Masterson, the companys strength in these core innovative therapeutic areas will allow the organization to accelerate growth following its recent transition in both leadership and ownership. As a portfolio company of STUCK Fund 1, based in Milwaukee, WI, Ardent Animal Health will continue to develop novel approaches for early disease detection and treatments, with a focus on precision medicine for pets in need.

We will continue to focus much of our strategy in creating novel products and services utilized in veterinary hospitals. We believe that this approach is key to the future of animal health. It is important not only for value creation but to ensure veterinarians have the ability to diagnose and treat their patients with the same leading-edge strategies underway in human health. Our animal family members deserve it.

Disclaimer Experimental Cancer Vaccines created by Ardent Animal Health are provided under 9 CFR 103.3 via USDA Center for Veterinary Biologics oversight for use under supervision/prescription of a licensed veterinarian. Safety & efficacy have not been yet established.

About Ardent Animal Health

Since 2016 Ardent Animal Health based near Lexington, KY, has provided advanced medical strategies to veterinary hospitals around the world. Ardent provides regenerative medicine treatments such as ActiStem Therapy and PureVet PRP to veterinarians for pain and disease in companion and equine patients. Additionally, Ardent Animal Health is pursuing advanced strategies for detection and treatment of canine cancer. Through creation of its own intellectual property and strategic licensing partners, the companys portfolio includes current and future offerings aimed to raise the standard for animal healthcare.

Home

About STUCK Fund 1

Ardent Animal Health represents an innovation-focused element of the STUCK Fund 1 portfolio, as Ardent competes in the fast-growing and recession-resistant pet health sector. STUCK Fund 1, based in Milwaukee, WI, was founded in 2014 to live out the lessons the investment firms founders learned from growing its business into an international, $100 million organization. STUCK founders were honored with numerous accolades in their prior ventures, including the Muskego Manufacturing Business of the Year award and the Waukesha Business Alliance Manufacturing Business of the Year honor, among several others. Currently, the investment firm supports like-minded entrepreneurs to accelerate and sustain the growth of their businesses.

About

Media Contact: Matt Yeich (859)885-7111 matt@ardentanimalhealth.com

Share article on social media or email:

Read the rest here:
MediVet Biologics Rebrands as Ardent Animal Health - PR Web

Good-Risk Group of Patients With Myeloma Saw Better Outcomes – Cancer Therapy Advisor

Researchers have used deep whole-genome sequencing (WGS) to identify genomic markers of a good-risk group of patients with multiple myeloma with prolonged survival. Specifically, patients found to have a low genomic scar score and chromosome 9 gain had superior outcomes.

In the study, researchers analyzed WGS data from a 2009 study from 183 patients with newly diagnosed myeloma who had been treated with lenalidomide, bortezomib, and dexamethasone alone or in combination with autologous stem cell transplant. These data were then integrated with clinical data.

The researchers calculated a genomic scar score (GSS) using allele-specific copy-number alterations. Patients with a total score of 5 or less were considered to have a low GSS.

On average, WGS identified 7343 single nucleotide variants, 235 small insertions, and 376 deletions per patient. Significant variations in mutational load were found, with hyperdiploid myeloma having the lowest and t(14;16) myeloma having the highest load (P =.004).

In all, patients with a low GSS had significantly longer median progression-free survival and overall survival than other patients. The researchers identified a genomically defined subgroup of patients accounting for about 17% of patients with low DNA damage (a low genomic scar score with chromosome 9 gain) and a superior outcome. These patients had 100% overall survival at 69 months.

Other characteristics of this subgroup included lower mutational load with significant contribution from age-related mutations and NRAS mutation. Specifically, patients with low GSS and chromosome 9 gain had significantly lower mutational load compared with other groups (P =.0002).

Interestingly, the superior outcome group identified here was independent of traditional clinical risk factors, such as ISS, response to treatment, and achievement of [minimal residual disease] negativity, the researchers wrote. Importantly, our study shows that, in addition to traditional risk markers, we can use genomic markers such as low GSS and gain9 to identify true low-risk groups.

Reference

Samur MK, Samur AA, Fulciniti M, et al. Genome-wide somatic alterations in multiple myeloma reveal a superior outcome group [published online July 20, 2020]. J Clin Oncol. doi: 10.1200/jco.20.00461

See the original post here:
Good-Risk Group of Patients With Myeloma Saw Better Outcomes - Cancer Therapy Advisor

‘Year of Preparations for the Next Fifty Years’ will contribute to country’s development process – Emirates News Agency

ABU DHABI, 3rd August, 2020 (WAM) -- In 2020, the UAEs achievements, most notably the launch of the Hope Probe to Mars and the operation of Unit 1 of the Barakah Nuclear Power Plant, have proven that the "Year of Preparations for the Next Fifty Years" will significantly contribute to the countrys development process.

Despite the difficult circumstances facing the world caused by the coronavirus, COVID-19, pandemic, the UAE has succeeded in turning challenges into opportunities for innovation and development, which is reflected in its approach to limiting the spread of the virus through a range of creative measures, such as developing technology to discover the virus using lasers that generate results in a record time, using stem cell therapy for patients, and participating in global efforts to find a vaccine.

In 2020, the UAEs achievements reflect the national ambitions and wisdom of its leadership. The Hope Probe project involved nearly 200 Emirati engineers and researchers, who worked hard for six years to fulfil the UAE's dream to reach the Red Planet.

The Barakah Nuclear Power Plant also highlights the UAEs efforts to build the capacities of national cadres in this sector. Nearly 244 employees work for the Federal Authority for Nuclear Regulation, FANR, with 67 percent being Emiratis, of which 45 percent are in leading and managerial positions. Women also account for over 40 percent of the Authoritys employees.

Once all four units of the plant are commercially operating, the UAE's Barakah Nuclear Energy Plant will produce up to 25 percent of the country's electricity requirements while in parallel preventing the release of 21 million tons of carbon emissions each year.

On the level of combating COVID-19, Emirati national cadres and institutions joined the front line since the first day to discover the first case in the country, and contributed to achieving milestones at the global level.

In May, a patent was granted by the Ministry of Economy for the development of an innovative and promising treatment for COVID-19 infections using stem cells. The treatment was developed by a team of doctors and researchers at the Abu Dhabi Stem Cell Center, ADSCC, and involves extracting stem cells from the patients own blood and reintroducing them after activating them.

QuantLase Imaging Lab, the medical-research arm of the Abu Dhabi Stock Exchange-listed International Holdings Company, IHC, announced that it has developed novel equipment which enables for much faster mass screenings, with test results available in seconds and allowing testing on a wider scale.

The technology will reinforce the UAEs position as a hub of research and innovation, as scientists around the world scramble to devise a faster method of testing for patients suspected to have been infected with the coronavirus and potentially identifying carriers before they become infectious.

The first World Health Organisation, WHO, enlisted global clinical Phase III trial of Sinopharm CNBGs inactivated vaccine to combat COVID-19 started in Abu Dhabi.

The worlds first Phase III trial is the result of a cooperation partnership between Abu Dhabi based G42 Healthcare, currently at the forefront of the battle against COVID-19 in the UAE, and Sinopharm CNBG, the worlds sixth-largest vaccine manufacturer, ranked 169th on the Fortune Global 500 list of 2018.

The trials are being operated by health practitioners from Abu Dhabi Health Services, SEHA, who are providing facilities at five of their clinics in Abu Dhabi and Al Ain in addition to a mobile clinic to ensure the trials are readily accessible to volunteers participating in the programme.

View post:
'Year of Preparations for the Next Fifty Years' will contribute to country's development process - Emirates News Agency